Have multiple conditions? Click here

New Clinical Trials for Hepatitis

While much is known about the disease from years of hepatitis clinical studies, there is renewed hope that advances in genetic engineering and improved antiviral medications may help greatly improve hepatitis treatments. Please review the list of current hepatitis clinical trials. If you have suffered from either acute or chronic bouts of hepatitis we would like to hear from you. Clinical trials are always at no cost to you, but may go a long way in helping to better treat you and future patients.
 

What is Hepatitis?

Hepatitis is an inflammation of the liver. Acute cases can usually heal with no medical treatment; chronic cases left untreated can progress to fibrosis (scarring) and cirrhosis. Symptoms of hepatitis include jaundice (yellowing of the skin and eyes), loss of appetite and a general feeling of being out of sorts. A chronic case is said to last six months or more and may result in enlargement of the liver. A patient with chronic hepatitis often suffers flu-like symptoms. In cirrhosis, the most advanced form of hepatitis, patients bruise and bleed easily, their legs swell and they have an accumulation of fluid in the abdomen.
 

Hepatitis Treatments

Hepatitis has several very different causes and treatment depends on the diagnosis. Hepatitis A, B, C, D, and E are viral. An example of a non-viral cause of hepatitis is toxoplasma. Excessive alcohol use and many medications can also cause hepatitis. Acute cases of hepatitis can be treated with rest and giving the body time to heal. For chronic cases interferon may be prescribed. This is a protein that combats viruses in the body. Unfortunately, it is an expensive drug with many side effects and therefore not the most viable hepatitis treatment. Some physicians prescribe a combination of antiviral drugs. In extreme cases a liver transplant may be required, but this is a last resort for treating hepatitis.

Have multiple conditions? Click here

Showing 1-100 of 846
There are 846 Hepatitis Clinical Trials
Name City State Zip
Hepatitis C Clinical Trial DeLand FL 32720
Hepatitis C Clinical Trial DeLand FL 32720
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Montgomery AL 36116
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Montgomery AL 36116
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin Montgomery AL 36116
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Dothan AL 36305
TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Birmingham AL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders Birmingham AL 35233
Virology Follow up Study in Subjects Previously Treated With Telaprevir Birmingham AL
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin Birmingham AL 35233
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults Birmingham AL 35294
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens Birmingham AL
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Tucson AZ 85721
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Tucson AZ 85721
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH) Tucson AZ 85712
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Phoenix AZ 85054
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Phoenix AZ
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Phoenix AZ 85054
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Phoenix AZ 85054
TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Peoria AZ
Hepatitis C Translating Initiatives for Depression Into Solutions No. Little Rock AR 72114
Racial Difference in HCV/Host Interactions Little Rock AR 72202
Racial Difference in HCV/Host Interactions Ventura CA 93003
Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients Ventura CA 93003
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Vallejo CA 94589
Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C Vallejo CA 94589
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Vallejo CA 94589
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults Torrance CA 90502
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma Stanford CA 94305
Genetic Analysis of Liver Cancer Stanford CA 94305
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Stanford CA 94305
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. Santa Clara CA 95051
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Santa Clara CA 95051
TMC435-TiDP16-C216 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Santa Clara CA 95051
TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Santa Clara CA 95051
TMC435HPC3007 - Phase III Trial of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy Santa Clara CA 95051
A Study on The Combination of RO5024048 And Ritonavir-Boosted Danoprevir With And Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR) Santa Clara CA 95051
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both Santa Clara CA 95051
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies Santa Clara CA 95051
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection Santa Clara CA 95051
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo Santa Clara CA 95051
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Santa Clara CA 95051
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens Santa Clara CA 95051
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection Santa Clara CA 95051
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection. Santa Clara CA 95051
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects Santa Clara CA 95051
Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients San Jose CA 95116
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care San Jose CA 95116
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant San Francisco CA 94115
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 San Francisco CA 94143
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection San Francisco CA 94143
Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy San Francisco CA 94110
HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B San Francisco CA 94115
HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B San Francisco CA 94143
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C San Francisco CA 94121
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C San Francisco CA 94115
Study of SCY-635, Pegasys and Copegus in Hepatitis C San Francisco CA 94115
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) San Francisco CA 94115
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) San Francisco CA 94110
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) San Francisco CA 94115
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C San Francisco CA 94143
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis San Francisco CA 94115
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection San Francisco CA 94115
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults San Francisco CA 94110
Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects San Francisco CA 94115
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C San Francisco CA 94115
Hepatitis B Research Network Adult Cohort Study San Francisco CA 94115
Hepatitis B Research Network Pediatric Cohort Study (HBRN) San Francisco CA 94143
Efficacy and Safety Study of DEB025/Alisporivir Combined to Standard Therapy (Peg-IFN and Ribavirin) in Chronic Hepatitis C Genotype 1 naïve Patients San Diego CA 92123
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders San Diego CA 92123
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders San Diego CA 92103
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C San Diego CA 92123
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C San Diego CA 92015
Study the Relationship Between Obesity and Hepatitis C Replication San Diego CA 92161
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen San Diego CA 92105
Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients San Diego CA 92105
Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients San Diego CA 92101
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C San Diego CA 92123
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis San Clemente CA 92673
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders San Clemente CA 92673
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis Sacramento CA 95817
A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B Pasadena CA 91105
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis Pasadena CA 91105
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders Pasadena CA 91105
Hepatitis B Research Network Adult Cohort Study Orange CA 92668
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C National City CA 91950
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy Los Angeles CA 90033
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy Los Angeles CA 90028
Increasing Hepatitis B Screening Among Korean Church Attendees Los Angeles CA 90095
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Los Angeles CA 90048
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV Los Angeles CA 90028
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis Los Angeles CA 90048
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects Los Angeles CA 90073
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Los Angeles CA 90048
Hepatitis C Translating Initiatives for Depression Into Solutions Los Angeles CA 90073
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia Los Angeles CA 90033
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults Los Angeles CA 90035
Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects Los Angeles CA 90036
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects Los Angeles CA 90048
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Los Angeles CA 90048

Showing 1-100 of 846
Alabama - Alaska - Arizona - Arkansas - California - Colorado - Connecticut - Delaware - Washington DC - Florida - Georgia - Hawaii - Idaho - Illinois - Indiana - Iowa - Kansas - Kentucky - Louisiana - Maine - Maryland - Massachusetts - Michigan - Minnesota - Mississippi - Missouri - Montana - Nebraska - Nevada - New Hampshire - New Jersey - New Mexico - New York - North Carolina - North Dakota - Ohio - Oklahoma - Oregon - Pennsylvania - Rhode Island - South Carolina - South Dakota - Tennessee - Texas - Utah - Vermont - Virginia - Washington - West Virginia - Wisconsin - Wyoming
For Sponsors: Promote Your Study | For Research Sites: Promote Your Site

Copyright 2012 Clinical Trials Institute, LLC | All Rights Reserved
Login
Forgot password?
Enter your email and we will resend your password
Register